Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2

García-Guerrero, J; Herrero, Agustín Ceba; Araújo, Rosa; Castellano, Juan C; Bedia, Miguel; Repricova, Grupo de Estudio

doi:10.1016/s0213-005x(04)73027-x

Cited by 5 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there have been only five studies examining ARV resistance among prisoners-two in the United States 13,14 and three in Europe. [15][16][17] Of the two studies conducted in the United States, 13 one focused on 67 seroconverters during incarceration and restricted surveillance to only four major mutations. 14 The second study surveyed only 25 ARV treatment-naive prisoners.…”

Section: Introductionmentioning

confidence: 99%

Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States

Menezes

Rosen

Wohl

et al. 2013

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Drug-resistant HIV complicates management of HIV infection. Although an estimated 14% of all HIV-positive persons pass through a prison or jail in the United States each year, little is known about the overall prevalence of antiretroviral (ARV) resistance in incarcerated persons. All genotypic sequence data on HIV-positive prisoners in the North Carolina (NC) Department of Corrections (DOC) were obtained from LabCorp. Screening for major resistance mutations in protease (PI) and reverse transcriptase (NRTI and NNRTI) was done using Genosure and the Stanford HIV Database. For subjects with multiple genotype reports, each mutation was counted only once and considered present on all subsequent genotypes. Between October 2006 and February 2010, the NC DOC incarcerated 1,911 HIV(+) individuals of whom 19.2% (n=367) had at least one genotype performed. The overall prevalence of a major resistance mutation was 28.3% (95% CI 23.7, 33.0). Among prisoners ever exposed to an ARV during incarceration (n=329) prevalence of a major resistance mutation was 29.8% (95% CI 24.9, 34.7); resistance by class was 20.4% (95% CI 16.0, 24.7) for NRTIs, 19.8% (95% CI 15.5, 24.1) for NNRTIs, and 8.8% (95% CI 5.8,11.9) for PIs. Single class drug resistance was most prevalent at 14.2% (10.2,17.7) followed by dual 12.5% (I8.9,16.0) and triple class 3.3% (1.4,5.3) resistance. The three most prevalent mutations were K103N 15.8% (12.0, 20.2), M184V 14.3% (10.7,18.5), and M41L 4.9% (2.8,7.8). In the NC DOC ARV resistance prevalence, dual and triple class drug resistance was moderate over the study period. Resistance to PIs was lower than NNRTIs and NRTIs, likely reflecting higher usage of these two classes or a lower barrier to resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States

Menezes

Rosen

Wohl

et al. 2013

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

García-Guerrero¹,

Hoya

Portilla³

et al. 2006

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

The aim of this cross-sectional study was to analyse the prevalence of HIV-1 drug-resistance mutations among HIV-1-infected prison inmates in Spain. Treatment-naive and treatment-experienced patients with an HIV RNA viral load of >/=2,000 copies/ml were included. To ensure that the study population was representative of the entire HIV-infected Spanish inmate population, a two-stage conglomerate for selection of the sample was used. In the first stage, 15 prisons were randomly selected, and in the second stage, 38 patients (30 treatment-experienced and 8 treatment-naive) per centre were randomly selected. Genotyping was performed by automatic sequencing. Resistance testing was performed on viral strains from 184 inmates from 12 prisons. Valid sequences were obtained from 133 inmates (90 treatment-experienced and 43 treatment-naive inmates). Most (92.5%) were men and had acquired HIV infection by intravenous drug use (91%); their mean age was 35 years. One or more key resistance mutations were detected in 5 (11.6%) treatment-naive and in 35 (38.6%) treatment-experienced patients. Among treatment-naive and treatment-experienced patients, resistance to nucleoside reverse transcriptase inhibitors was found in 3 (6.9%) and in 20 (22.2%) patients, respectively, resistance to non-nucleoside reverse transcriptase inhibitors in 3 (6.9%) and in 21 (23.3%) patients, and resistance to protease inhibitors in 3 (6.9%) and in 14 (15.5%) patients. Multidrug resistance was detected in 1 of the 43 (2.3%) treatment-naive patients. These findings support the use of resistance testing in HIV-infected inmates who must begin antiretroviral therapy, given the high rate of primary resistance to drugs frequently included in the initial treatment regimens.

show abstract

Antiretroviral Treatment in Correctional Facilities

Pontali¹

2005

HIV Clinical Trials

View full text Add to dashboard Cite

Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2

Cited by 5 publications

References 6 publications

Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States

Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

Antiretroviral Treatment in Correctional Facilities

Contact Info

Product

Resources

About